Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on obesity care, announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer on June 29, 2026. The move aims to bolster the company's leadership team as it advances late-stage clinical trials and navigates the evolving obesity treatment landscape. Tregoning's expertise is expected to support Kailera's mission to deliver new treatment options for people living with obesity.

Ron Renaud, President and Chief Executive Officer of Kailera, emphasized the strategic value of Tregoning's appointment. "Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission," Renaud said. Her role will focus on fostering stakeholder engagement and supporting a policy environment conducive to innovation in obesity treatment.

Tregoning's Background and Experience

Kathleen Tregoning brings over two decades of experience leading global corporate affairs organizations. She previously served as Chief Corporate Affairs Officer and Head of Commercial Strategy at Cerevel Therapeutics, where she guided the company through significant growth prior to its acquisition by AbbVie in 2024. Before that, she held the position of Executive Vice President, External Affairs at Sanofi, leading global external engagement strategies and healthcare policy development.

Tregoning's career also includes a decade-long tenure at Biogen, where she ultimately served as Senior Vice President, Corporate Affairs. Her responsibilities spanned communications, patient advocacy, public policy, and government affairs. Earlier in her career, she worked as a professional staff member in health policy for multiple committees of the United States Congress.

Educational and Board Roles

Tregoning graduated from Stanford University with a degree in International Relations and holds a graduate degree in Public Policy from the Harvard Kennedy School. She currently serves as an independent director on the boards of Compass Pathways (NASDAQ: CMPS) and Spero Therapeutics (NASDAQ: SPRO).

Kailera Therapeutics' Pipeline

Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action. Its lead product candidate, ribupatide injection (KAI-9531), is a once-weekly injectable GLP-1/GIP receptor dual agonist currently in global Phase 3 trials. The company is also developing a once-daily oral formulation of ribupatide, along with KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist.

Kailera's vision is to deliver category-leading obesity management medications. The company is headquartered in Waltham, MA.